Numerous studies have evaluated the use of low-dose aspirin (LDA) to reduce rates of pre-eclampsia and adverse perinatal outcomes in women considered at risk of pre-eclampsia. A new study recommends that these women should receive LDA after 12 weeks of gestation to reduce the rates of pre-eclampsia, preterm birth and fetal growth restriction.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Aspirin for Prevention of Preeclampsia
Drugs Open Access 16 October 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 122, 1122–1131 (2013).
Barton, J. R. & Sibai, B. M. Prediction and prevention of recurrent preeclampsia. Obstet. Gynecol. 112, 359–372 (2008).
Meher, S. & Alfirevic, Z. Aspirin for pre-eclampsia; beware of subgroup meta-analysis. Ultrasound Obstet. Gynecol. 41, 479–485 (2013).
Askie, L. M., Duley, L., Henderson-Smart, D. J., Stewart, L. A. & PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369, 1791–1798 (2007).
LeFevre, M. L. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventative Task Force recommendation statement. Ann. Intern. Med. http://dx.doi.org/10.7326/M14-1884.
[No authors listed] CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9,364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 343, 619–629 (1994).
[No authors listed] ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. Br. J. Obstet. Gynaecol. 103, 39–47 (1996).
Caritis, S. et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child. Health and Human Development Network of Maternal–Fetal Medicine Units. N. Engl. J. Med. 338, 701–705 (1998).
Acknowledgements
The author wishes to acknowledge his assistant A. I. Rosas.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Sibai, B. Low-dose aspirin to reduce the risk of pre-eclampsia?. Nat Rev Endocrinol 11, 6–8 (2015). https://doi.org/10.1038/nrendo.2014.199
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2014.199
This article is cited by
-
Aspirin for Prevention of Preeclampsia
Drugs (2017)